InspiroGene by McKesson has been selected as the specialty pharmacy partner for Iovance Biotherapeutics Inc.'s Amtagvi®, marking the first cell therapy approved for solid tumors. This partnership aims to increase access for patients with advanced melanoma. By leveraging Biologics by McKesson's extensive experience in specialty pharmacy and oncology, the collaboration seeks to reduce administrative burdens for providers and expand patient access to this innovative therapy. Amtagvi is the only FDA-approved one-time tumor-infiltrating lymphocyte $(TIL)$ therapy for solid tumors, providing a personalized treatment option for patients who have undergone immune checkpoint inhibitor and targeted therapy. Through this partnership, Iovance aims to efficiently deliver life-extending therapies to more patients.